Discussion
cancer, tumor, HER2-positive primary tumors, HER2-negative
CANCER, TUMOR, HEPATIC METASTASES
Recent advances in HER2-targeted therapy have prompted the need for increased understanding of HER2 expression levels, ideally in each tumor lesion in each patient. It is important to consider the availability and ease of use of the method to become broadly useful. Visualization and quantification of the expression of molecular targets for precision treatment of cancer within theranostics is typically associated with the use of PET This study demonstrated that injections of An unexpected finding in this study was a higher hepatic uptake in patients with HER2-positive primary tumors compared with patients with HER2-low or HER2-negative ones when 500 µg was injected (Figure Studies with the The injection of an increased mass of Affibody molecules may raise a reasonable question of whether this could affect the uptake of HER2-targeting drugs. However, anti-HER2 Affibody molecules bind to a HER2 epitope that is different from the epitopes of the most commonly used anti-HER2 monoclonal antibodies, trastuzumab and pertuzumab An important observation was that the hepatic metastases were clearly visualized in patient 15 (Figure This study was designed to explore the impact of protein mass dose for detecting HER2 expression in light of current recommendations for the selection of first-line HER2-targeting therapies 